(Press-News.org) A rigorous analysis of more than 20,000 medical records concludes that erectile dysfunction drugs, such as Viagra, are not a cause of melanoma, an often deadly form of skin cancer, despite the higher risk for the disease among users of these drugs. A detailed report on the research findings is to be published in the Journal of the American Medical Association online June 23.
The analysis, led by researchers at NYU Langone Medical Center and its Laura and Isaac Perlmutter Cancer Center, of medical records for some 20,235 mostly white men suggests instead that the likely source of the observed uptick in malignant melanoma risk among users of erectile dysfunction drugs is socioeconomic and lifestyle based.
"What our study results show is that groups of men who are more likely to get malignant melanoma include those with higher disposable incomes and education -- men who likely can also afford more vacations in the sun -- and who also have the means to buy erectile dysfunction medications, which are very expensive," says lead study investigator and NYU Langone urologist Stacy Loeb, MD, MSc.
"While medications for erectile dysfunction come with serious risk of a drop in blood pressure if taken together with other medicines called nitrates, overall they are safe medications, and our results suggest that physicians should not be concerned that the drugs cause melanoma," says Loeb, an assistant professor at NYU Langone and member of its Perlmutter Cancer Center.
"Physicians should still screen men for melanoma risk, but they do not need to add use of erectile dysfunction drugs to their list of screening criteria," says Loeb, whose latest study was prompted by a highly cited 2014 analysis in 14 men who had taken Viagra and were later diagnosed with melanoma.
Among the more than 20,000 men whose records were studied, 4,065 were found to have malignant melanoma between 2006 and 2012. Among these men were 2,148 who had used any of the three main drugs for erectile dysfunction -- Viagra (also known as sildenafil), Levitra (vardenafil), and Cialis (tadalafil) -- and among them, some 435 had the skin cancer.
Researchers who led the analysis say that while there was a greater statistical risk of developing malignant melanoma among erectile dysfunction drug users (an overall increased risk of 21 percent for having filled a single prescription), a closer look at the numbers revealed no increased risk among those men with the most prescriptions. Researchers say that a "dose relationship" -- i.e., the more drugs taken the higher the risk -- would usually be expected if the drugs were a direct cause of the cancer.
The NYU Langone team and their colleagues in Sweden also found no correlation between the more advanced stages of the disease and drug usage. The only detected association was between any use of the drugs and the earliest stages of melanoma, further weakening the idea that the drugs were behind the overall observed increase in risk.
Moreover, researchers say their calculations of statistical risk would have been expected to be different for other types of skin cancer if the drugs -- known collectively as phosphodiesterase type-5 inhibitors, or PDE5i for short -- actually caused the disease. Instead, researchers found almost the same increased risk for another type of skin cancer, basal cell carcinoma (19 percent higher risk), which is linked to different biological pathways than the shared pathway involved in PDE5i use and malignant melanoma.
"When used appropriately, erectile dysfunction medications are very effective and improve the quality of life for many men, so men should know it is doubtful that taking these medications puts them at greater risk of getting skin cancer," says Loeb, who encourages her male patients to always practice skin cancer prevention by minimizing their exposure to the sun.
For the study, researchers matched and analyzed the medical records of men whose care was being monitored by the National Melanoma Register and the Prescribed Drug Register in Sweden, one of the few countries in the world taking a population-wide approach to battling melanoma and other types of cancer, and for which no comparable North American data source exists.
INFORMATION:
Funding support for the study was provided by grants from the Swedish Research Council (825-2012-5047), the Swedish Cancer Foundation (11-0471), Vasterbotten County Council, and the Lion's Cancer Research Foundation at Umea University in Umea, Sweden. Additional funding support was provided by the Laura and Isaac Perlmutter Cancer Center, and the Louis Feil Charitable Lead Trust. Loeb has received speaking fees about a prostate cancer medication manufactured by Bayer, which also markets Levitra.
In addition to Loeb, other investigators involved in the study were Yasin Folkvaljon, MD, at Uppsala University Hospital in Uppsala, Sweden; Mats Lambe, MD, PhD, at the Karolinska Institute in Stockholm, Sweden; Hans Garmo, PhD, at King's College in London, UK; Christian Ingvar, MD, PhD, at Lund University in Helsingborg, Sweden; David Robinson, MD, PhD, and senior study investigator Par Stattin, MD, PhD, both at Umea University in Umea, Sweden.
For more information, go to:
http://www.med.nyu.edu/biosketch/loebs01#
http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.2015.6604
DURHAM, N.C. - Heart attack patients age 65 and older who have reduced heart function might still benefit from implanted defibrillators, according to a Duke Medicine study published in the Journal of the American Medical Association. But fewer than 1 in 10 eligible patients actually get a defibrillator within a year of their heart attacks, the study found.
Advanced age, transitions in care between the hospital and an outpatient clinic, and a mandatory waiting period to get a defibrillator after a heart attack were the most likely factors for low rates of use, according ...
Among Medicare patients who experienced a heart attack from 2007 to 2010, fewer than 1 in 10 eligible patients with low ejection fraction (a measure of how well the left ventricle of the heart pumps blood with each beat) received an implantable cardioverter-defibrillator (ICD) within 1 year after the heart attack, even though ICD implantation was associated with a lower risk of death at 2 years after implantation, according to a study in the June 23/30 issue of JAMA.
More than 350,000 people experience sudden cardiac death in the United States annually. Clinical trials ...
Among men in Sweden, use of erectile dysfunctions drugs with phosphodiesterase type 5 inhibitors was associated with a modest but significant increased risk of malignant melanoma, although the pattern of association raises questions about whether this association is causal, according to a study in the June 23/30 issue of JAMA.
Phosphodiesterase type 5 (PDE5; an enzyme), the target of oral erectile dysfunction (ED) drugs, is part of a pathway that has been implicated in the development of malignant melanoma. This has raised questions whether PDE5 inhibitors used to treat ...
Among extremely preterm infants, early screening for the vascular disorder patent ductus arteriosus before day 3 of life was associated with a lower risk of in-hospital death and pulmonary hemorrhage, but not with differences in other severe complications, according to a study in the June 23/30 issue of JAMA.
The ductus arteriosus is a blood vessel in a fetus that bypasses pulmonary circulation by connecting the pulmonary artery directly to the ascending aorta. It usually closes within 72 hours of birth in most normal-term infants. However, failure to close is common ...
In an analysis of the findings of nearly 80 randomized trials that included about 6,500 participants, there was moderate-quality evidence to support the use of cannabinoids (chemical compounds that are the active principles in cannabis or marijuana) for the treatment of chronic pain and lower-quality evidence suggesting that cannabinoids were associated with improvements in nausea and vomiting due to chemotherapy, sleep disorders, and Tourette syndrome, according to a study in the June 23/30 issue of JAMA.
Medical cannabis refers to the use of cannabis or cannabinoids ...
An analysis of edible medical marijuana products from 3 major metropolitan areas found that many had lower amounts of key substances than labeled, which may not produce the desired medical benefit, while others contained significantly more of a certain substance than labeled, placing patients at risk of experiencing adverse effects, according to a study in the June 23/30 issue of JAMA.
As the use of cannabis (marijuana) for medical purposes has expanded, a variety of edible products for oral consumption has been developed. An estimated 16 percent to 26 percent of patients ...
In a proof-of-concept study, a team led by a Johns Hopkins researcher reports that the vast majority of edible cannabis products sold in a small sample of medical marijuana dispensaries carried labels that overstated or understated the amount of delta-9-tetrahydrocannabinol (THC).
Though the scope of the study was small, the researchers say, the results of the study suggest some medical cannabis patients could be unintentionally overdosing or are being cheated by mislabeled products.
"If this study is representative of the medical cannabis market, we may have hundreds ...
BOSTON, June 23 -- In a Viewpoint published today in the Journal of the Medical Association (JAMA), researchers from the Friedman School of Nutrition Science and Policy at Tufts University and Boston Children's Hospital call on the federal government to drop restrictions on total fat consumption in the forthcoming 2015 Dietary Guidelines for Americans.
Co-authors Dariush Mozaffarian, M.D., Dr.P.H., dean of the Friedman School, and David Ludwig, M.D., Ph.D., director of the New Balance Foundation Obesity Prevention Center at Boston Children's Hospital, highlight a key, ...
ANN ARBOR--A months-long literature search that involved tracking down century-old scientific papers and translating others from Czech and French helped University of Michigan ecologist Meghan Duffy answer a question she'd wondered about for years.
The early studies helped Duffy determine that the microscopic aquatic parasite she first observed as a graduate student, and which her research team had recently collected in more than a dozen southeast Michigan lakes, is the same fungus-like organism that a French biologist first described in 1903.
"The longer historical ...
U.S. consumers are often urged to "buy American," and some special interest groups even claim that buying foreign products is inappropriate, or even immoral. But when it comes to buying domestic products, positive feelings for one's own country may play a more important role than negative feelings toward another, according to a new study in the Journal of International Marketing.
"National identity--feeling proud to be, say, an American--and believing that Americans should not buy foreign products influence attitudes toward domestic products, but the impact of national ...
